References
- Škalko-Basnet N. Biologics: the role of delivery systems in improved therapy. Biologics. 2014;8:107–114.
- Lazaro Cebas A, Cortijo Cascajares S, Pablos Bravo S, et al. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use. J Buon. 2017;22(2):334–339.
- Bell CF, Lau M, Lee M, et al. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE. Clin Rheumatol. 2021;40(2):581–590.
- Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836–842.
- Li Z, Easton R. Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. MAbs. 2018;10(1):18–33.
- U.S. Food and Drug Administration. Applying human factors and usability engineering to medical devices. [Internet]. 2016; [cited 2020 Dec 10]. Available from: https://www.fda.gov/media/80481/download.
- U.S. Food and Drug Administration. Human factors studies and related clinical study considerations in combination product design and development. [Internet]. 2016; [cited 2020 Dec 10]. Available from: https://www.fda.gov/media/96018/download.
- American National Standards Institute/Association for the Advancement of Medical Instrumentation. HE75:2009 Human factors engineering – Design of medical devices. Arlington (VA): Association for the Advancement of Medical Instrumentation [Internet]. 2009; [cited 2020 Dec 10]. Available from: https://www.techstreet.com/mss/products/preview/923488.
- Gupta SP, Pidgeon A. An analytical approach to identifying potential use-related issues concerning a medical device under development. J Med Eng Technol. 2016;40(3):61–71.
- Patel R, Mehta M, Pipalava P, et al. Insights into human factor studies conducted for US FDA-approved biological combination products. Expert Opin Drug Deliv. 2019;16(12):1333–1353.
- Drugs@FDA: FDA-Approved Drugs. [Internet]; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process.
- U.S. Food and Drug Administration. Human factors results and label and labeling review for Skyrizi (risankizumab-rzaa) injection, 70 mg/0.83 mL. BLA 761105. [Internet]. 2018; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761105Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labelling and human factors results review for Hadlima (adalimumab-bwwd) injection 40 mg/0.8 mL. BLA 761059. [Internet]. 2019; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761059Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling and human factors study results review for Abrilada (Adalimumab-afzb) injection, 40 mg/0.8 mL, 20 mg/0.4 mL and 10 mg/0.2 mL. BLA 761118. [Internet]. 2019; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factors, label, labeling, and packaging review for Kevzara (Sarilumab) injection 150 mg/1.14 mL, 200 mg/1.14 mL. BLA 761037. [Internet]. 2016. [cited 2020 Dec 10]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761037Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling review for Praluent (Alirocumab) injection, 75 mg/mL, 150 mg/mL. BLA 125559 [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125559Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label, labeling, and human factors review for Cyltezo (Adalimumab-adbm) 40 mg/0.8 mL injection. BLA 761058. [Internet]. 2017; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761058Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label, labeling, and usability study review for Plegridy Pen (Peginterferon beta-1a) injection 63mcg/0.5 mL, 94 mcg/0.5 mL, 125 mcg/0.5 mL. BLA 125499. [Internet]. 2014; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125499Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factor results and label and labeling review for Ajovy (Fremanezumab-vfrm) injection 225 mg/1.5 mL (150 mg/mL). BLA 761089. [Internet]. 2018; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761089Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factors, label, labeling, and packaging review for Dupixent (Dupilumab) injection 300 mg/2 mL (150 mg/mL) prefilled syringe (PFS). BLA 761055. [Internet]. 2017; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761055Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling review for Repatha (Evolocumab) injection, 140 mg/mL [Prefilled syringe] repatha sureclick (Evolocumab) injection, 140 mg/mL [Autoinjector]. BLA 125522. [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125522Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factors results and label and labeling review for Aimovig (erenumab-aooe) injection, 70 mg/mL autoinjector and prefilled syringe. BLA 761077. [Internet]. 2018; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761077Orig1s000OtherR.pdf.
- Zarxio (Filgrastim). Prescribing Information. Sandoz Inc. [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125553lbl.pdf.
- U.S. Food and Drug Administration. Human factors, label, labeling, and packaging review for Zarxio (Filgrastim-sndz) injection, 300 mcg/0.5mL and 480 mcg/0.8 mL. BLA 125553. [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factors, label, and labeling review for Basaglar (Insulin glargine [rDNA origin]) injection, 100 units/mL. NDA 205692. [Internet]. 2014; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling and human factors results review for Soliqua (Insulin glargine and lixisenatide injection, 300 units and 150 mcg per 3 mL pen and insulin glargine and lixisenatide injection, 300 units and 99 mcg per 3 mL pen. NDA 208673. [Internet]. 2016; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208673Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. CDRH human factors review for Tresiba (Insulin degludec [rDNA origin]) injection flextouch 100 units/mL and 200 units/mL pen injectors. NDA 203314. [Internet]. 2012; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313Orig1s000_203314Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling and human factors results review for Xultophy (Insulin degludec and liraglutide) injection, 300 units and 10.8mg liraglutide per 3mL pen (100 units insulin degludec and 3.6mg liraglutide per mL). NDA 208583. [Internet]. 2016; [cited 2010 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208583Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Label and labeling review for Toujeo Solostar (Insulin glargine [rDNA origin]) injection, 300 units per mL. NDA 206538. [Internet]. 2014; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factors, label, and labeling review for Saxenda (Liraglutide) injection, 6 mg/mL. NDA 206321. [Internet]. 2014; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000OtherR.pdf.
- Basaglar (Insulin glargine) injection. Prescribing Information. Lilly USA and Boehringer Ingelheim Pharmaceuticals Inc. [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205692lbl.pdf.
- Soliqua 100/33 (Insulin glargine and lixisenatide injection). Prescribing Information. Sanofi-Aventis US LLC. [Internet]. 2016; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208673s000lbl.pdf.
- Saxenda (Liraglutide [rDNA origin] injection). Prescribing Information. Novo Nordisk Inc. [Internet]. 2014; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf.
- Toujeo (Insulin glargine injection) U-300. Prescribing Information. Sanofi-Aventis US LLC. [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538s000lbl.pdf.
- Xultophy 100/3.6 (Insulin degludec and liraglutide injection). Prescribing Information. Novo Nordisk Inc. [Internet]. 2016; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208583s000lbl.pdf.
- Tresiba (Insulin degludec injection). Prescribing Information. Novo Nordisk Inc. [Internet]. 2015; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf.
- Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(Suppl 2):S3–S18.
- U.S. Food and Drug Administration. Human factors study, label and labeling review for Tanzeum (Albiglutide) for injection, 30 mg and 50 mg. BLA 125431. [Internet]. 2014; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000OtherR.pdf.
- U.S. Food and Drug Administration. Human factor results and label and labeling review for Adlyxin (lixisenatide) injection. NDA 208471. [Internet]. 2018; [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208471Orig1s000OtherR.pdf.